Drug Testing Locations - Plympton, MA

Drug Testing in Plympton, MA

Plympton, Massachusetts Statistics

In 2021, Plympton, MA, saw a 15% increase in opioid-related overdoses, according to the Plymouth County Sheriff's Department.

Plympton, located in Plymouth County, recorded 25 drug-related arrests in 2022, a slight decrease from the previous year.

A community survey in 2022 indicated that 12% of Plympton, MA, residents reported misuse of prescription drugs.

Plymouth County, which includes Plympton, reported a 20% increase in naloxone use by first responders in 2022.

The town of Plympton, part of the Plymouth County, had 3 drug-related deaths recorded in 2021.

In 2022, Plympton schools, part of Plymouth County, reported a 5% rate of drug-related incidents, according to local school reports.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Employers in Plympton, MA & Drug Testing Policies

Employers in Plympton, MA, are increasingly adopting drug testing policies to ensure a safe and productive workplace. These policies often align with guidelines provided by the Substance Abuse and Mental Health Services Administration (SAMHSA), emphasizing the importance of maintaining a drug-free environment for all employees.

Additionally, local businesses may require pre-employment drug screenings, regular random testing, or testing based on reasonable suspicion. Companies frequently collaborate with the Massachusetts Executive Office of Labor and Workforce Development to ensure compliance with state and federal regulations while supporting employees who seek assistance for substance use disorders.

Government Efforts with Drug Problems in Plympton, MA

The Plympton, MA local government collaborates with the Massachusetts Department of Public Health to address drug abuse issues through community outreach and education programs. These efforts aim to increase awareness and provide support for those affected by drug addiction.

Efforts at the county level include initiatives by the Plymouth County Sheriff's Department, which organizes drug take-back events and enhances law enforcement training to effectively combat drug-related crimes. The focus is on creating a supportive environment for recovery and prevention.

Local Drug Busts & News in Plympton, MA

Recent drug busts in Plympton, MA, highlight the ongoing battle against illegal substances in the region. In 2022, a coordinated effort by the Plymouth County Drug Task Force led to the arrest of several individuals involved in a drug trafficking ring, which significantly impacted the local supply of illicit drugs.

Community events focused on drug prevention and awareness are also prevalent in Plympton. These events, sponsored by local organizations, aim to educate residents about the dangers of drug abuse and provide resources for those seeking help. Programs often feature speakers from law enforcement and healthcare professionals from nearby Plymouth County institutions.

Occupational Health Services

Accredited Drug Testing offers fast, reliable employment screening services in Plympton, MA. Trusted by employers nationwide for accurate results and exceptional service.

Massachusetts DOT/Non DOT Physicals

Massachusetts Vision Tests

Massachusetts Audiograms

Massachusetts Respirator Fit Tests

Massachusetts Lift Tests

Massachusetts Background Checks

Clinical Testing Services

TB Testing in MA

Diabetes Testing in MA

Infectious Disease Testing in MA

Sickle Cell Anemia Testing in MA

Women/Men's Health Testing in MA

Resources & Citations

Massachusetts Substance Use Helpline

River Run Healthcare

South Shore Health Behavioral Programs

High Point Treatment Center

Cutter Health Behavioral Health

Baystate Health

Mass General BRAVE Program

Beth Israel Deaconess Plymouth

American Psychiatric Association

Berkshire Healthcare Behavioral Health

Drug Testing Near Plympton, MA

Duxbury, MA

East Bridgewater, MA

North Lakeville, MA

Bridgewater, MA

South Duxbury, MA

Hanson, MA

Middleborough Center, MA

North Plymouth, MA

Middleborough, MA

Carver, MA

Kingston, MA

Halifax, MA

Frequently Asked Questions

Customer Reviews